P2RX7 and amyotrophic lateral sclerosis: Among the possible reasons is that P2X7 could be centrally but favorably “less inhibited” by the poor CNS-permeable BBG during the pre/early symptomatic phase of ALS, when the most potent and CNS-penetrant antagonists are generally provided, and when the onset of ALS is even anticipated by the genetic deletion of the receptor.